China Nuokang Bio-Pharmaceutical Inc., a biopharmaceutical company, engages in the research, development, manufacture, marketing, and sale of hospital-based medical products in China. The company’s principal products include Baquting, a hemocoagulase product derived from Bothrops atrox venom to treat and prevent bleeding; and Kaitong, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders, and post-surgery thrombosis. It also offers Aiduo, a cardiovascular stress imaging agent; and Aiwen, an anti-arrhythmic agent for the diagnosis and treatment of paroxysmal supraventricular tachycardia, as well as provides dipyridamole aspirin capsules for the prevention of strokes. In addition, the company’s products under development comprise a hemocoagulase derived from Agkistrodon acutus snake venom; lanthanum polystyrene sulfonate product candidate for the treatment of hyperphosphatemia; and adenosine as a myocardial protection agent for various cardiovascular-related clinical settings. Further, its product pipeline includes product candidates under development that address the medical needs for bleeding control and hematological, cardiovascular, and cerebrovascular disease diagnosis, treatment, and prevention. It sells its products to pharmaceutical distributors. China Nuokang Bio-Pharmaceutical Inc. was founded in 1997 and is based in Shenyang, China. As of February 7, 2013, China Nuokang Bio-Pharmaceutical Inc. was taken private.